2004 Annual Meeting | Clinical Trials in Dementia
| 06:00 PM - 06:15 PM |
Introduction
|
|
| 06:15 PM - 06:45 PM |
Current Treatment
Rachelle S. Doody, MD, PhD |
|
| 06:45 PM - 07:15 PM |
Treatments Under Development
Leon J. Thal, MD |
|
| 07:15 PM - 07:45 PM |
Primary Prevention
Steven T. DeKosky, MD, FAAN |
|
| 07:45 PM - 08:00 PM |
Questions and Answers
|
| Leon J. Thal, MD | No disclosure on file |
| No disclosure on file | |
| Rachelle S. Doody, MD, PhD | Dr. Doody has received personal compensation for serving as an employee of F. Hoffman-LaRoche. Dr. Doody has stock in F. Hoffman-LaRoche. |
| Steven T. DeKosky, MD, FAAN | Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acumen. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. DeKosky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail Pharamceuticls. Dr. DeKosky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaccinex, Inc. Dr. DeKosky has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Up-To-Date. Dr. DeKosky has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics . |